PF-4708671

Name: PF-4708671
Brand: Selleck Chemicals
SKU: S2163
Rating: 5 (20 reviews)

For research use only.

Licensed and Manufactured by Pfizer Catalog No.S2163

20 publications

Molecular Weight(MW): 390.41

PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with K_i/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. PF-4708671 induces autophagy. First S6K1-specific inhibitor to be reported.

Selleck's PF-4708671 has been cited by 20 publications

Nat Commun, 2020, 11(1):3200

PubMed: 32581239 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Cell Mol Life Sci, 2020, 10.1007/s00018-020-03617-5

PubMed: 32804243 ( click the link to review the publication )

FASEB J, 2020, 10.1096/fj.202001183R

PubMed: 32686868 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Theranostics, 2019, 9(19):5464-5477

PubMed: 31534497 ( click the link to review the publication )

Oncogene, 2019, 38(35):6270-6282

PubMed: 31316145 ( click the link to review the publication )

Platelets, 2019, 30(2):241-250

PubMed: 29257917 ( click the link to review the publication )

Nutr Metab (Lond), 2018, 10.1186/s12986-018-0268-9

PubMed: 29743930 ( click the link to review the publication )

Cell Death Dis, 2017, 8(1):e2553

PubMed: 28079897 ( click the link to review the publication )

Front Immunol, 2017, 7:685

PubMed: 28138329 ( click the link to review the publication )

Oncotarget, 2016, 7(8):9163-74

PubMed: 26824321 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(3):799-809

PubMed: 25573956 ( click the link to review the publication )

J Immunol, 2015, 195(6):2529-39

PubMed: 26276876 ( click the link to review the publication )

J Biol Chem, 2015, 290(9):5592-605

PubMed: ( click the link to review the publication )

Toxicol Lett, 2015, 233(2):102-113

PubMed: 25597859 ( click the link to review the publication )

Cell Immunol, 2015, 298(1-2):9-17

PubMed: 26302934 ( click the link to review the publication )

Cell Signal, 2015, 27(11):2191-200

PubMed: 26210887 ( click the link to review the publication )

PLoS One, 2014, 9(2):e90388

PubMed: 24587347 ( click the link to review the publication )

Oncotarget, 2014, 5(10):3145-58

PubMed: 24762669 ( click the link to review the publication )

Purity & Quality Control

Choose Selective S6 Kinase Inhibitors

Biological Activity

Description

Targets

p70 S6K1 ^[1]
(Cell-free assay)

160 nM

In vitro

PF-4708671 is a piperazinyl-pyrimidine analogue and the first S6K1-specific inhibitor. PF-4708671 does not significantly inhibit the activity of the closely related S6K2 isoform or a number of other AGC kinases (Akt1, Akt2, PKA, PKCα, PKCϵ, PRK2, ROCK2, RSK1, RSK2 or SGK1) . PF-4708671 prevents the S6K1-mediated phosphorylation of S6 protein in response to IGF-1 (insulin-like growth factor 1), while having no effect upon the PMA-induced phosphorylation of substrates of the highly related RSK (p90 ribosomal S6 kinase) and MSK (mitogen- and stress-activated kinase) kinases. PF-4708671 is also found to induce phosphorylation of the T-loop and hydrophobic motif of S6K1, an effect that is dependent upon mTORC1 (mTOR complex 1). PF-4708671 does not affect activity of mTORC1. ^[1]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
BHT-101	MoPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnXWTWM2OD1yLkiyNFI1KM7:TR?=	MoPUV2FPT0WU
UACC-893	NUfHTmhyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFLPRW9KSzVyPUWuNVk5QDZizszN	M1yxTHNCVkeHUh?=
A427	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUXOVWh{UUN3ME21MlczPTZ5IN88US=>	MWDTRW5ITVJ?
OCUB-M	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnYTWM2OD14Lk[2NVAzKM7:TR?=	NXnhPZY4W0GQR1XS
SW684	NES4NFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NITCN5JKSzVyPUeuOVIzPjhizszN	MXzTRW5ITVJ?
SK-LMS-1	M2SxXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\DTWM2OD17LkCxN\|AzKM7:TR?=	MkjLV2FPT0WU
CP50-MEL-B	MoW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTlwM{C0NVkh\|ryP	MXPTRW5ITVJ?
NCI-H1651	M3G3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWLHXFFwUUN3ME2xNE4xOjd4IN88US=>	M2TOSnNCVkeHUh?=
ABC-1	NULP[IdoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTFyLkGwN\|ch\|ryP	M3LUUHNCVkeHUh?=
OE19	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTFyLkG3N\|Mh\|ryP	NHPJU3NUSU6JRWK=
DSH1	M{HlTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M373XmlEPTB;MUCuPFg4QSEQvF2=	NV3hT4pQW0GQR1XS
SW13	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml7wTWM2OD1zMT65N\|E6KM7:TR?=	MYDTRW5ITVJ?
MDA-MB-453	NIXFRZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF[3SmpKSzVyPUGyMlE3ODNizszN	MontV2FPT0WU
647-V	NIX1[4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTF{LkO1PFIh\|ryP	MVTTRW5ITVJ?
NCI-H2342	NX;O[pR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUTZblZGUUN3ME2xNk4{QTl3IN88US=>	MUjTRW5ITVJ?
LB2241-RCC	M{fKR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NILhRVJKSzVyPUGyMlU4PzlizszN	NF:xN3JUSU6JRWK=
UACC-257	MljDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4nn[mlEPTB;MUOuOFQ2OyEQvF2=	NIr5fmNUSU6JRWK=
NCI-H661	M4LL[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTvTWM2OD1zMz62OFQ6KM7:TR?=	M1\QS3NCVkeHUh?=
FADU	M1PqRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGfjepdKSzVyPUGzMlY6QTJizszN	NVrGVYtJW0GQR1XS
A2780	M{[zOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGXoXphKSzVyPUGzMlgxPDFizszN	NV;5ZZFEW0GQR1XS
NCI-H1793	NIXGeHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1TXcWlEPTB;MUSuOFA5PSEQvF2=	NV;NNFJbW0GQR1XS
TE-8	NWXQbFYzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXjMWI1WUUN3ME2xOU4{PDZ3IN88US=>	MoOxV2FPT0WU
HGC-27	NGXENoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFvydVJKSzVyPUG2MlE3PDRizszN	NG\sboNUSU6JRWK=
MMAC-SF	M3nKXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3TwNGlEPTB;MUeuN\|czPyEQvF2=	M{\kZXNCVkeHUh?=
Calu-6	NFz1dG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmPTTWM2OD1zOD6xOVE{KM7:TR?=	NIHqW\|BUSU6JRWK=
HUTU-80	NIO0fXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXLXWIY{UUN3ME2xPE4{QTV7IN88US=>	M2fXeHNCVkeHUh?=
SAS	M4DjZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTF6Lk[0OVUh\|ryP	NYP5OGpWW0GQR1XS
IST-MES1	NWjySlRbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoTsTWM2OD1zOD62OVA5KM7:TR?=	M33lS3NCVkeHUh?=
C3A	M3;jemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTF6Lke5NVkh\|ryP	MWDTRW5ITVJ?
ES3	M3LUcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1i0PWlEPTB;MUiuPFM3PCEQvF2=	NXzSSmJuW0GQR1XS
HSC-2	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4rEVGlEPTB;MUmuOlU1OSEQvF2=	M4\2TXNCVkeHUh?=
T47D	MkfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmHGTWM2OD1{MD6xOFg2KM7:TR?=	M2TMVXNCVkeHUh?=
EW-7	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mkm0TWM2OD1{MD64OVg5KM7:TR?=	MXXTRW5ITVJ?
LN-405	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmSzTWM2OD1{MD64PVY2KM7:TR?=	NWjOUFJNW0GQR1XS
U031	NVL0T4RFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHnQ[WlKSzVyPUKxMlQ5ODJizszN	NYjsXnBnW0GQR1XS
A549	M1yxR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXvEW4RzUUN3ME2yNU45PDlzIN88US=>	MlHGV2FPT0WU
RMG-I	NILIZ5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{jjTWlEPTB;MkKuNlY3QCEQvF2=	NUL0OI9wW0GQR1XS
BT-474	NF\lZXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWnYSlVLUUN3ME2yNk43PTVzIN88US=>	MU\TRW5ITVJ?
NB69	MoTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\MeXRxUUN3ME2yN{4yPTJizszN	NUmxZplTW0GQR1XS
NB7	NUjzWWk4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnPETWM2OD1{ND6xPFgh\|ryP	NYizSYp{W0GQR1XS
HCC1569	NVv2dnpUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF;kb45KSzVyPUK0MlYyOjVizszN	M2q0bnNCVkeHUh?=
MEL-JUSO	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH[xN4tKSzVyPUK0MlY6ODhizszN	M3H5enNCVkeHUh?=
MDA-MB-175-VII	M2jw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnTzTWM2OD1{NT6yOVE4KM7:TR?=	NY\MfGJUW0GQR1XS
HCC1419	NEnWRYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTJ3Lk[wNFMh\|ryP	Ml;TV2FPT0WU
Ca9-22	NHvpNppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlH1TWM2OD1{NT62OFMzKM7:TR?=	NVvTO\|RiW0GQR1XS
KGN	M1fR[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF;zU5dKSzVyPUK1Mlc2PDdizszN	MmnoV2FPT0WU
LB373-MEL-D	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3rOSGlEPTB;Mk[uNVk{QCEQvF2=	NInBfoVUSU6JRWK=
NCI-H1755	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MliyTWM2OD1{Nj64PFQyKM7:TR?=	M4LNU3NCVkeHUh?=
D-423MG	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmeyTWM2OD1{Nz6wO\|E2KM7:TR?=	NFjPW\|hUSU6JRWK=
DK-MG	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVi3Tlg1UUN3ME2yPE44QDR4IN88US=>	NFj5SnpUSU6JRWK=
NCI-H1623	M{f3UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{Lp[mlEPTB;MkiuPFM1OiEQvF2=	MUjTRW5ITVJ?
KU-19-19	NUPFNJNQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRTJ6Lkm5OUDPxE1?	NXnSWpBTW0GQR1XS
C-33-A	M{[3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4DDVmlEPTB;MkmuNlE6QCEQvF2=	NFvMUJFUSU6JRWK=
SCC-4	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2jiVmlEPTB;M{CuN\|M2PCEQvF2=	MX\TRW5ITVJ?
MG-63	NIWxPHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1nUd2lEPTB;M{CuOVk6PCEQvF2=	M3fBUnNCVkeHUh?=
LNCaP-Clone-FGC	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HyfGlEPTB;M{GuOFkzOSEQvF2=	M{LxcHNCVkeHUh?=
CAPAN-1	MlPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTNzLkWyPFYh\|ryP	MlPGV2FPT0WU
GI-ME-N	NVrMd\|hTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWn1RpBkUUN3ME2zNU42OzV\|IN88US=>	NVGyNpA1W0GQR1XS
RERF-LC-MS	NXn6SotmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXSdnBKSzVyPUOyMlY4PDdizszN	NVTQb2h2W0GQR1XS
KLE	NGPJPINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTN\|LkSzN\|Qh\|ryP	M{H5OnNCVkeHUh?=
KNS-81-FD	NFPzTIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlnaTWM2OD1\|Mz61NFA5KM7:TR?=	MVXTRW5ITVJ?
DOK	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{jMVWlEPTB;M{SuOlYyOiEQvF2=	NWLHVWRFW0GQR1XS
ACHN	NVTHOlkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{ewUGlEPTB;M{WuNVU5QCEQvF2=	NVSwO3REW0GQR1XS
KYSE-520	Ml3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH;aWGxKSzVyPUO1MlI{PjFizszN	NUf1XHFPW0GQR1XS
SBC-5	NIXP[IpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmPyTWM2OD1\|NT61NVE3KM7:TR?=	MlTKV2FPT0WU
NCI-H28	M4Czbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFfDdVJKSzVyPUO1MlY3QTVizszN	M{fQNHNCVkeHUh?=
ES7	NWfYXFBxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3mT2FMUUN3ME2zOk4zOjR7IN88US=>	NHLBUoFUSU6JRWK=
A172	Ml[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTN4LkSxPFch\|ryP	MnfHV2FPT0WU
UM-UC-3	M2rnbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{nONGlEPTB;M{euPFc1PiEQvF2=	NFK0bllUSU6JRWK=
LXF-289	NWfUeW91T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV3HWIE4UUN3ME2zPE4xODR5IN88US=>	MXfTRW5ITVJ?
KP-4	MoL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTN6LkS3N\|kh\|ryP	NYH5UWxrW0GQR1XS
TE-1	NXviXmhqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHfxWm5KSzVyPUO5MlY2QDlizszN	MkHTV2FPT0WU
G-402	MmHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFvQbWJKSzVyPUSwMlA3OSEQvF2=	Mmf5V2FPT0WU
786-0	Mn64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFS5OVJKSzVyPUSwMlkxQTZizszN	MX3TRW5ITVJ?
K5	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4LafWlEPTB;NEGuN\|Y5PiEQvF2=	MYnTRW5ITVJ?
SK-N-DZ	MmjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTRzLkO4NlMh\|ryP	MmXmV2FPT0WU
OVCAR-4	MmjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVnRR3hiUUN3ME20NU44PTZ6IN88US=>	MWTTRW5ITVJ?
T84	M3:xWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTBcXBlUUN3ME20Nk4yOjZ\|IN88US=>	MnrsV2FPT0WU
GCIY	NWPlPWhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3yxPWlEPTB;NEOuNFgxOyEQvF2=	NHXKc41USU6JRWK=
BB49-HNC	M{PQcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVWyTFY6UUN3ME20N{4{OzR6IN88US=>	M3XCdnNCVkeHUh?=
SNU-C2B	M4HCZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHXoWXBKSzVyPUSzMlY1OzZizszN	MkXyV2FPT0WU
TE-6	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2DqUGlEPTB;NEOuPFg6PCEQvF2=	MmPLV2FPT0WU
23132-87	NEHneXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{CwdmlEPTB;NESuNlk4QCEQvF2=	MnfEV2FPT0WU
DMS-53	NHTjR5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrnSXF1UUN3ME20OE4{Ozh2IN88US=>	MVzTRW5ITVJ?
ONS-76	Mo[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVHJR\|UxRTR2Lke2OlEh\|ryP	NVfldVhPW0GQR1XS
DMS-273	NEnXZm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVjFRo5uUUN3ME20OE46PDNizszN	NUXaSploW0GQR1XS
COLO-824	NH7OenNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DQfWlEPTB;NEWuPFc4PSEQvF2=	NXrEcY55W0GQR1XS
DMS-114	NVnUW21LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnqzTWM2OD12NT64PVI4KM7:TR?=	NXXCZW9jW0GQR1XS
YKG-1	NGL1c4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTR4LkCzOVUh\|ryP	M4PNS3NCVkeHUh?=
RH-18	M3XH[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3m3b2lEPTB;NE[uN\|c{OyEQvF2=	NX7lUmhZW0GQR1XS
NCI-H1355	M3W5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1TaUWlEPTB;NE[uOlE5KM7:TR?=	MVfTRW5ITVJ?
NCI-H2170	NWPuOFd3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTR5Lke1PFQh\|ryP	NH;EZo9USU6JRWK=
OC-314	NVn0T49HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTR5Lki0O\|gh\|ryP	MlT3V2FPT0WU
NCI-H2030	M2LoeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXfPWo9DUUN3ME20O{45QTB4IN88US=>	M1zuc3NCVkeHUh?=
22RV1	M1rjcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoDFTWM2OD12Nz65NFE2KM7:TR?=	NVuzRYpMW0GQR1XS
G-401	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHfVSVJKSzVyPUS4MlQ1OTVizszN	M3P2[3NCVkeHUh?=
YAPC	NGe2T5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW\BcJVZUUN3ME20PU45ODd\|IN88US=>	MUXTRW5ITVJ?
SW1573	NF34Xm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTVyLkK0N\|Uh\|ryP	NYTURVFRW0GQR1XS
COLO-792	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHv3VnhKSzVyPUWwMlYzOzdizszN	NYHHcGFVW0GQR1XS
KNS-62	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTVyLke1NFgh\|ryP	MV\TRW5ITVJ?
NB5	NVfKWXg2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX\JR\|UxRTVzLkS1NFkh\|ryP	M3TZW3NCVkeHUh?=
CP66-MEL	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlryTWM2OD13MT62OFA5KM7:TR?=	NVHENIdnW0GQR1XS
CaR-1	NXfFN2ZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoPFTWM2OD13Mj6wOlA3KM7:TR?=	M1\YTXNCVkeHUh?=
CAL-54	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{myRWlEPTB;NUKuNVExOiEQvF2=	NUjOO5I1W0GQR1XS
8305C	M1HnRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\nTYtKSzVyPUWyMlMyPSEQvF2=	NHrLXmNUSU6JRWK=
Calu-3	MlO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTV{LkO3N\|Mh\|ryP	MVvTRW5ITVJ?
AU565	Mo\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2q3VGlEPTB;NUKuOVUxQSEQvF2=	NVfnV3dCW0GQR1XS
CW-2	M170dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkK0TWM2OD13Mj64OlU1KM7:TR?=	NH\0O\|RUSU6JRWK=
BEN	M{[3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPMTWM2OD13Mz63PFYzKM7:TR?=	NUf0ZnZzW0GQR1XS
NCI-H1975	NELKVmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoLzTWM2OD13Mz64PVY3KM7:TR?=	NHTuXIxUSU6JRWK=
HCT-116	M{i5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoPUTWM2OD13ND6wN\|I4KM7:TR?=	NH7NUWxUSU6JRWK=
SH-4	NWX1WXJGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYjJR\|UxRTV2LkGzPEDPxE1?	MkHMV2FPT0WU
NCI-H1693	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnX6TWM2OD13ND6yNVA{KM7:TR?=	MkLLV2FPT0WU
BPH-1	M37SPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXLs[4VNUUN3ME21OU4zQDl{IN88US=>	MlfOV2FPT0WU
CAMA-1	NUiwNpBFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PGXGlEPTB;NUWuPFEyPiEQvF2=	MmewV2FPT0WU
A388	M3nwWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnqNolKSzVyPUW2MlA6QDVizszN	M1vmT3NCVkeHUh?=
C2BBe1	M13ve2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4rS[GlEPTB;NU[uNlY{PCEQvF2=	MmTOV2FPT0WU
GAMG	NXzkN2FTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEjOeoNKSzVyPUW2MlU6PTVizszN	MVHTRW5ITVJ?
MKN28	NFPuNYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX\PO2V7UUN3ME21Ok45ODF\|IN88US=>	NYDEPHZVW0GQR1XS
VA-ES-BJ	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFrSbFFKSzVyPUW2Mlg4PDVizszN	NFOySIFUSU6JRWK=
HuCCT1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7JRmdKSzVyPUW3MlA1QTJizszN	NVG3fVJwW0GQR1XS
BFTC-905	NVfUSI4xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3kVGNUUUN3ME21O{4zQDl6IN88US=>	MlvnV2FPT0WU
LS-123	NFTwN5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\YR4FKSzVyPUW3MlU3PjhizszN	M1HvWHNCVkeHUh?=
LB996-RCC	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlrzTWM2OD13OD6wNlg4KM7:TR?=	NX[3T5Z[W0GQR1XS
NCI-H1048	NXzRO2FuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4nK[mlEPTB;NUiuNlE5QCEQvF2=	NEnnT5BUSU6JRWK=
COR-L105	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{HIZ2lEPTB;NUiuO\|M{PyEQvF2=	M4DwOHNCVkeHUh?=
OVCAR-8	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFLPUINKSzVyPUW5MlE4OTZizszN	MWLTRW5ITVJ?
SK-N-FI	NVLmPHdYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2nqcmlEPTB;NUmuN\|IxPyEQvF2=	MYrTRW5ITVJ?
MES-SA	MnLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYHvRYRuUUN3ME21PU41PTB7IN88US=>	MXXTRW5ITVJ?
SCC-9	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGiweIJKSzVyPUW5MlQ4PTNizszN	MXHTRW5ITVJ?
EFO-27	NIfkNppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTV7Lkm0N{DPxE1?	M3LNTXNCVkeHUh?=
GT3TKB	M3\0Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUP1c2YxUUN3ME22NE43ODR6IN88US=>	NH3zbZlUSU6JRWK=
HCC38	NF7EeGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1Xy[mlEPTB;NkGuOFM4QSEQvF2=	MnjIV2FPT0WU
MLMA	Ml7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTZzLk[xOlMh\|ryP	MXLTRW5ITVJ?
D-566MG	M{TJRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVPJR\|UxRTZ\|LkWyNlQh\|ryP	NI\zOXpUSU6JRWK=
SF295	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mlm1TWM2OD14Mz62OlU2KM7:TR?=	NWHPZWFGW0GQR1XS
ES4	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLsTWM2OD14ND60O\|E6KM7:TR?=	NX;USYJIW0GQR1XS
CAKI-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MonITWM2OD14ND61O\|IyKM7:TR?=	MnHwV2FPT0WU
OAW-28	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn:wTWM2OD14ND65OlQ4KM7:TR?=	NFfUcFFUSU6JRWK=
NCI-H460	NH\BXGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1jOPGlEPTB;NkWuNFg6PyEQvF2=	NFezZlhUSU6JRWK=
JAR	MkPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1XDRWlEPTB;NkWuOVUyPiEQvF2=	MYrTRW5ITVJ?
SNU-449	MoWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2GzU2lEPTB;NkWuO\|YyPiEQvF2=	MWHTRW5ITVJ?
D-392MG	NUKxemNiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LHTmlEPTB;NkWuPVQ{PCEQvF2=	M4H0NXNCVkeHUh?=
EW-22	NUXsXIkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIf4bplKSzVyPU[2MlM6PSEQvF2=	MWHTRW5ITVJ?
GCT	NWfuRno{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\qV4l{UUN3ME22O{4xPDR\|IN88US=>	MXrTRW5ITVJ?
NOS-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXjBPXJYUUN3ME22O{43QDZ5IN88US=>	M{\wc3NCVkeHUh?=
RH-1	M4HPVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzUdnhKSzVyPU[4MlU2PTlizszN	M4LjNHNCVkeHUh?=
HuH-7	M4j3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjubZluUUN3ME22PU4yODB{IN88US=>	M2TIfnNCVkeHUh?=
NUGC-3	M1XVc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkDkTWM2OD15MD65OlQ1KM7:TR?=	Mof5V2FPT0WU
IST-SL1	MmizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1vXRWlEPTB;N{GuNlMzPCEQvF2=	NFrUPIlUSU6JRWK=
SHP-77	MlfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2WxPGlEPTB;N{KuNVE6KM7:TR?=	NYrUO\|dEW0GQR1XS
SW1116	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXfJR\|UxRTd{LkG0NFch\|ryP	MVTTRW5ITVJ?
LK-2	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVv2Zo45UUN3ME23Nk45PjF{IN88US=>	M{ntS3NCVkeHUh?=
U-2-OS	NYnDTFYzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1GwN2lEPTB;N{OuNVgzQCEQvF2=	MUHTRW5ITVJ?
KYSE-150	MkLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTd\|Lk[xNVgh\|ryP	NXzRRotSW0GQR1XS
U251	NHXpVYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MljvTWM2OD15Mz64NVY5KM7:TR?=	M{\SWHNCVkeHUh?=
HT-1080	Mn;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTd2LkK1O\|Qh\|ryP	NES2[WNUSU6JRWK=
NCI-H1437	Mki3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3rZRmlEPTB;N{SuOlMzPiEQvF2=	MWrTRW5ITVJ?
HPAF-II	MnvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXT0O21zUUN3ME23OE43PDF3IN88US=>	MUHTRW5ITVJ?
Becker	M1jRdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEDobo5KSzVyPUe1MlEyODVizszN	M3n0S3NCVkeHUh?=
PANC-10-05	NUDLdoNzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYm4OXVuUUN3ME23OU4zQDZ3IN88US=>	M3XXRXNCVkeHUh?=
TYK-nu	MkX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF3G[IVKSzVyPUe1MlMyODJizszN	NUS2PXdPW0GQR1XS
SKG-IIIa	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\NRXVuUUN3ME23OU4{OzRzIN88US=>	MmP5V2FPT0WU
NCI-H1993	MlGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIX1R2ZKSzVyPUe1Mlc{QTdizszN	MnnqV2FPT0WU
S-117	MmfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoHZTWM2OD15NT63OVUh\|ryP	NFLKPZVUSU6JRWK=
HuO9	NVvHdVh3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPLPGRKSzVyPUe2MlAxPDhizszN	MUHTRW5ITVJ?
CAL-51	NFXET4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4nVV2lEPTB;N{[uNVAxPiEQvF2=	M3fGdXNCVkeHUh?=
BT-20	M{DtUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYrEenRNUUN3ME23Ok4zOTZ6IN88US=>	NXvxUm9PW0GQR1XS
LB831-BLC	NVe3NGU6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlu0TWM2OD15Nj6zNlE4KM7:TR?=	MXjTRW5ITVJ?
LB1047-RCC	NFLRUppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTd4Lke2NVkh\|ryP	MWDTRW5ITVJ?
ES8	M1rJdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTd6LkCwO\|Mh\|ryP	MYTTRW5ITVJ?
UMC-11	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3rsWWlEPTB;N{iuNFg5PCEQvF2=	MX3TRW5ITVJ?
NCI-H226	NHjTS4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTd6LkGzNVUh\|ryP	NWHQ[pdFW0GQR1XS
IGROV-1	NUjVdJJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mon6TWM2OD15OD61OVUh\|ryP	NF3Ke\|ZUSU6JRWK=
BHY	NIDhN5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTd7LkW5OkDPxE1?	MVvTRW5ITVJ?
MKN45	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRThyLkOxO\|Qh\|ryP	NH;0SFJUSU6JRWK=
IA-LM	NHvnXVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVO3b5h4UUN3ME24NE4{PTFzIN88US=>	MYjTRW5ITVJ?
WM-115	NUPHSodKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRThzLkSxNVQh\|ryP	NHjMWGxUSU6JRWK=
VMRC-RCZ	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4PkXmlEPTB;OEGuOFQzPSEQvF2=	MXfTRW5ITVJ?
NCI-H2291	NXyxWZBNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFjPWpBKSzVyPUixMlY5PDJizszN	MkW2V2FPT0WU
MCF7	Mne1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlPrTWM2OD16Mz6yPFk4KM7:TR?=	NFvoWY9USU6JRWK=
639-V	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrGTGdKSzVyPUi0MlYyOjlizszN	NYr5d5d1W0GQR1XS
RT4	NI[3UpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTh3LkK0NFMh\|ryP	MYTTRW5ITVJ?
NCI-H2405	NFPweG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmjHTWM2OD16NT6yPVk4KM7:TR?=	MUfTRW5ITVJ?
CAL-33	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\TUmZDUUN3ME24OU43OzF3IN88US=>	Ml7VV2FPT0WU
BT-549	NH74OGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml;LTWM2OD16NT65N\|gzKM7:TR?=	M1fD[HNCVkeHUh?=
HT-1197	NXrlWnBOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVrJR\|UxRTh6LkGwO\|ch\|ryP	NE[xVVBUSU6JRWK=
G-361	NYPRbpozT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkC0TWM2OD16OD6xOFc1KM7:TR?=	MVTTRW5ITVJ?
LS-411N	NG\jPXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTh7LkOzPFgh\|ryP	MlLMV2FPT0WU
HT-144	NXTybIpFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoPyTWM2OD16OT61PVkzKM7:TR?=	NEXWe3hUSU6JRWK=
DJM-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTh7Lki4OFUh\|ryP	NHLzOIFUSU6JRWK=
CAL-12T	NFvBdYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTlyLke4PVUh\|ryP	NITucFRUSU6JRWK=
MKN7	NG\nU3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn\zTWM2OD17MT6zOVUyKM7:TR?=	MlPtV2FPT0WU
HuP-T3	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1PBPWlEPTB;OU[uNVAxPCEQvF2=	NYL4R2F5W0GQR1XS
SK-MG-1	NWK5VYVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLFTWM2OD17Nj6xN\|Q5KM7:TR?=	MkXMV2FPT0WU
NCI-H2347	NIXiOlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHjFSodKSzVyPUm4MlExPDJizszN	NIHJZoNUSU6JRWK=
SW872	NV\He3R{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEfXdndKSzVyPUGwNE41PTZizszN	Mn7jV2FPT0WU
COLO-829	M3zpSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH\6VJRKSzVyPUGwNE42PTNizszN	MULTRW5ITVJ?
MC-IXC	NV3FNGpVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTFyMD62NVUh\|ryP	NVjmVpdQW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pS6 / S6 / pS6K / S6K1 / pAKT / AKT ; PubMed: 28626016 J Neurosci Western blot of cell lysates from neurons treated with PF-4708671, rapamycin, and Torin-2, individually or in combination for the indicated times. p-mTOR / mTOR / p-p70S6K / p70S6K ; PubMed: 30423811 Int J Mol Sci As determined using Western blotting, the phospho-p70S6K (p-p70S6K) inhibitor (PF-4708671) reduced the expression of phospho-mTOR (p-mTOR) and p-p70S6K in SCC-4 and SCC-25 cells. SCC-4 and SCC-25 cells were not treated as negative control (NC) or treated with 20 µM PF-4708671 for 6 h (6 h), 12 h (12 h), 18 h (18 h), 1 day (1 d), 2 days (2 d), and 3 days (3 d). Western blot analysis was performed to examine the expression levels of p-mTOR, mTOR, p-p70S6K, p70S6K, and β-actin.	28626016 30423811
Growth inhibition assay	Cell viability; PubMed: 30423811 Int J Mol Sci Inhibitory effects of various doses (0.5, 1, 2, 5, 10, 20, and 40 µM) of PF-4708671 on SCC-4 (B) and SCC-25 (C) cells were assessed using MTT assay after 72 h of treatment. Data presented are the mean and standard error of the mean of three independent experiments. * p < 0.05, p < 0.01, and * p < 0.001 indicate the statistical significance of differences between cells with and without treatment. t (red and * for SCC-4 and blue , * and *** for SCC-25).	30423811

Protocol

References

[1] Pearce LR, et al. Biochem J, 2010, 431(2), 245-255.

Solubility (25°C)

In vitro	DMSO	30 mg/mL (76.84 mM)
	Ethanol	8 mg/mL (20.49 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG400+0.5% Tween80+5% propylene glycol For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download PF-4708671 SDF

Molecular Weight	390.41
Formula	C₁₉H₂₁F₃N₆
CAS No.	1255517-76-0
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CCC1=CN=CN=C1N2CCN(CC2)CC3=NC4=C(N3)C=C(C=C4)C(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Whether the in vivo formula "30% PEG400+0.5% Tween80+5% Propylene glycol" for S2163 is suitable for i.p. or not?
Answer:
The formula "30% PEG400+0.5% Tween80+5% Propylene glycol" on our website is an oral one. It is a suspension.

S6 Kinase Signaling Pathway Map

Related S6 Kinase Products

LY2584702 ^New

LY2584702 is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.
LY2584702 Tosylate ^New

LY2584702 Tosylate is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.
CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs. CHIR99021 functions as a Wnt/β-catenin activator and induces autophagy.
BI-D1870

BI-D1870 is an ATP-competitive inhibitor of S6 ribosome for RSK1/2/3/4 with IC50 of 31 nM/24 nM/18 nM/15 nM in cell-free assays, respectively; 10- to 100-fold selectivity for RSK than MST2, GSK-3β, MARK3, CK1 and Aurora B. BI-D1870 exhibits anticancer attributes including the generation of reactive oxygen species (ROS) and increases in endoplasmic reticulum (ER) stress and autophagy.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus, AY 22989, NSC-2260804) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
MK-2206 2HCl

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. MK-2206 2HCl induces autophagy and apoptosis in cancer cells. Phase 2.

Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.
CHIR-99021 (CT99021) HCl

CHIR-99021 (CT99021) HCl is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs Cdc2 and ERK2. CHIR-99021 is a potent pharmacological activators of the Wnt/beta-catenin signaling pathway. CHIR-99021 significantly rescues light-induced autophagy and augments GR, RORα and autophagy-related proteins.
LY294002

LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.
Everolimus (RAD001)

Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay. Everolimus induces cell apoptosis and autophagy and inhibits tumor cells proliferation.

Choose Your Country or Region

By Signaling Pathways

By product type

PF-4708671